Department of Diagnostic Pathology, Shizuoka Cancer Center Hospital, Sunto, Japan.
Department of Dermatology, Hyogo Cancer Center, Akashi, Japan.
J Cutan Pathol. 2023 Aug;50(8):739-747. doi: 10.1111/cup.14470. Epub 2023 May 25.
The clinicopathologic and genetic features of cutaneous melanoma with a BRAF V600K mutation are not well-known. We aimed to evaluate these characteristics in comparison with those associated with BRAF V600E.
Real-time polymerase chain reaction (PCR) and/or the MassARRAY® system were used to detect BRAF V600K in 16 invasive melanomas and confirm BRAF V600E in another 60 cases. Immunohistochemistry and panel next-generation sequencing were used to evaluate protein expression and tumor mutation burden, respectively.
The median age of melanoma patients harboring the BRAF V600K mutation (72.5 years) was higher than those with the BRAF V600E (58.5 years). The two groups also differed in sex (13/16 [81.3%] male in the V600K group vs. 23/60 [38.3%] in V600E) and in the frequency of scalp involvement (8/16 [50.0%] in V600K vs. 1/60 [1.6%] in V600E). The clinical appearance was similar to a superficial spreading melanoma. Histopathologically, non-nested lentiginous intraepidermal spread and subtle solar elastosis were observed. One patient (1/13, 7.7%) had a pre-existing intradermal nevus. Diffuse PRAME immunoexpression was seen in only one (14.3%) of seven tested cases. Loss of p16 expression was observed in all 12 cases (100%) analyzed. The tumor mutation burden was 8 and 6 mutations/Mb in the two tested cases.
Melanoma carrying the BRAF V600K mutation showed the predominance on the scalp of elderly men, lentiginous intraepidermal growth, subtle solar elastosis, possible existence of intradermal nevus component, frequent loss of p16 immunoexpression, limited immunoreactivity for PRAME, and intermediate tumor mutation burden.
BRAF V600K 突变的皮肤黑色素瘤的临床病理和遗传特征尚不清楚。我们旨在评估这些特征与与 BRAF V600E 相关的特征相比。
使用实时聚合酶链反应 (PCR) 和/或 MassARRAY®系统检测 16 例浸润性黑色素瘤中的 BRAF V600K,并在另外 60 例中确认 BRAF V600E。免疫组织化学和面板下一代测序分别用于评估蛋白质表达和肿瘤突变负担。
携带 BRAF V600K 突变的黑色素瘤患者的中位年龄(72.5 岁)高于携带 BRAF V600E 的患者(58.5 岁)。两组在性别(V600K 组 16/16 [81.3%] 为男性,V600E 组 60/60 [38.3%] 为女性)和头皮受累频率(V600K 组 8/16 [50.0%],V600E 组 1/60 [1.6%])方面也存在差异。临床表现类似于浅表扩散性黑色素瘤。组织病理学上观察到非巢状的痣样表皮内扩散和细微的太阳弹性纤维变性。一名患者(13/16,7.7%)有预先存在的真皮内痣。在测试的七个病例中,只有一个(14.3%)表现出弥漫性 PRAME 免疫表达。在分析的 12 个病例中,所有病例(100%)均观察到 p16 表达缺失。两个测试病例的肿瘤突变负担分别为 8 和 6 个突变/Mb。
携带 BRAF V600K 突变的黑色素瘤在老年男性的头皮上占主导地位,具有痣样表皮内生长、细微的太阳弹性纤维变性、可能存在真皮内痣成分、p16 免疫表达缺失频繁、PRAME 免疫反应有限,以及中间肿瘤突变负担。